HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (Rapid PDF) All Versions of this Article: CJN.01610407v1 3/1/133    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gilbertson, D. T. Articles by Collins, A. J. Search for Related Content PubMed PubMed Citation Articles by Gilbertson, D. T. Articles by Collins, A. J. Related Collections Related Article

Received April 6, 2007
Accepted on October 16, 2007

ORIGINAL ARTICLES

Hemoglobin Level Variability: Associations with Mortality

David T. Gilbertson ^*1, James P. Ebben ^*, Robert N. Foley ^*, Eric D. Weinhandl ^*, Brian Bradbury , and Allan J. Collins ^*

*Chronic Disease Research Group, Minneapolis Medical Research Foundation, Minneapolis, Minnesota; Hennepin County Medical Center, Minneapolis, Minnesota; University of Minnesota, Minneapolis, Minnesota; and Department of Epidemiology, Amgen, Inc., Thousand Oaks, California

¹ To whom correspondence should be addressed. E-mail: dgilbertson{at}cdrg.org.

	Abstract

Background/objectives: Awareness of hemoglobin level variability in dialysis patients is increasing, as is interest in its potential implications. In this retrospective, national study of associations between the degree of hemoglobin level variability in the first 6 mo of 2004 and subsequent mortality rates in the following 6 mo, 159,720 hemodialysis patients receiving epoetin therapy were studied.

Design, setting, participants, measurements: Monthly hemoglobin values were categorized as low (L; < 11 g/dl), intermediate (I; 11 to 12.5 g/dl), and high (H; >12.5 g/dl). Variability groups were classified on the basis of the lowest and highest hemoglobin categories seen during the 6-mo observation period: low-low (L-L), 1.4%; intermediate-intermediate (I-I), 6.0%; high-high (H-H), 2.3%; low-intermediate (L-I), 18.3%; intermediate-high (I-H), 31.7%, and low-high (L-H), 40.2%.

Results: On multivariate analysis, adjusted hazards ratios for subsequent mortality events were as follows: I-I, 1.0 (reference category); I-H, 1.02 (95% confidence interval [CI] 0.95 to 1.11); H-H, 1.06 (95% CI 0.93 to 1.21); L-H, 1.19 (95% CI 1.10 to 1.28); L-I, 1.44 (95% CI 1.33 to 1.56), and L-L, 2.18 (95% CI 1.93 to 2.45). Persistently and transiently low hemoglobin levels and highly variable hemoglobin levels were associated with increased risk of death; transiently and persistently high hemoglobin levels were not associated with increased risk of death. Bayesian modeling indicated that 3 mo with hemoglobin levels <11 g/dl may be associated with of increased risk of death.

Conclusions: Number of months with hemoglobin values below the target range, rather than hemoglobin variability itself, may be the primary driver of increased risk of death. Further research is needed to distinguish cause from effect and to understand the underlying mechanisms.

This article has been cited by other articles:

				A. Besarab, W. H. Horl, and D. Silverberg Iron Metabolism, Iron Deficiency, Thrombocytosis, and the Cardiorenal Anemia Syndrome Oncologist, September 1, 2009; 14(suppl_1): 22 - 33. [Abstract] [Full Text] [PDF]

				N. C. Boudville, O. Djurdjev, I. C. Macdougall, A. L.M. de Francisco, G. Deray, A. Besarab, P. E. Stevens, R. G. Walker, P. Urena, P. Inigo, et al. Hemoglobin Variability in Nondialysis Chronic Kidney Disease: Examining the Association with Mortality Clin. J. Am. Soc. Nephrol., July 1, 2009; 4(7): 1176 - 1182. [Abstract] [Full Text] [PDF]

				T. J. Arneson, D. Zaun, Y. Peng, C. A. Solid, S. Dunning, and D. T. Gilbertson Comparison of methodologies to characterize haemoglobin variability in the US Medicare haemodialysis population Nephrol. Dial. Transplant., May 1, 2009; 24(5): 1378 - 1383. [Full Text] [PDF]

				B. D. Bradbury, M. D. Danese, M. Gleeson, and C. W. Critchlow Effect of Epoetin Alfa Dose Changes on Hemoglobin and Mortality in Hemodialysis Patients with Hemoglobin Levels Persistently below 11 g/dL Clin. J. Am. Soc. Nephrol., March 1, 2009; 4(3): 630 - 637. [Abstract] [Full Text] [PDF]

				R. Minutolo, P. Chiodini, B. Cianciaruso, A. Pota, V. Bellizzi, D. Avino, S. Mascia, S. Laurino, V. Bertino, G. Conte, et al. Epoetin Therapy and Hemoglobin Level Variability in Nondialysis Patients with Chronic Kidney Disease Clin. J. Am. Soc. Nephrol., March 1, 2009; 4(3): 552 - 559. [Abstract] [Full Text] [PDF]

				K. Kalantar-Zadeh and G. R. Aronoff Hemoglobin Variability in Anemia of Chronic Kidney Disease J. Am. Soc. Nephrol., March 1, 2009; 20(3): 479 - 487. [Abstract] [Full Text] [PDF]

				A. L. M. de Francisco, P. Stenvinkel, and S. Vaulont Inflammation and its impact on anaemia in chronic kidney disease: from haemoglobin variability to hyporesponsiveness NDT Plus, January 1, 2009; 2(suppl_1): i18 - i26. [Abstract] [Full Text] [PDF]

				I. C. Macdougall, K.-U. Eckardt, and F. Locatelli Reply Nephrol. Dial. Transplant., December 1, 2008; 23(12): 4071 - 4072. [Full Text] [PDF]

				S. M. Brunelli, K. E. Lynch, E. D. Ankers, M. M. Joffe, W. Yang, R. I. Thadhani, and H. I. Feldman Association of Hemoglobin Variability and Mortality among Contemporary Incident Hemodialysis Patients Clin. J. Am. Soc. Nephrol., November 1, 2008; 3(6): 1733 - 1740. [Abstract] [Full Text] [PDF]

				A. K. Singh Anemia of Chronic Kidney Disease Clin. J. Am. Soc. Nephrol., January 1, 2008; 3(1): 3 - 6. [Full Text] [PDF]